Beaumont Doctor Appointed to FDA Gastrointestinal Drugs Advisory Committee
Dr. Mitchell Cappell will make recommendations for FDA approval or disapproval to the Commissioner of Food and Drugs.
Mitchell Cappell, M.D., Ph.D., chief, Gastroenterology, Beaumont Hospital, Royal Oak and professor, Oakland University William Beaumont School of Medicine, has been selected as one of the seven physicians on the U.S. Food and Drug Administration Gastrointestinal Drugs Advisory Committee.
Dr. Cappell, a Southfield resident, is part of an 11-member committee that evaluates data on the safety and effectiveness of marketed and investigational human drug products for use in treatment of gastrointestinal diseases. As an advisory committee member, he will make recommendations for FDA approval or disapproval to the Commissioner of Food and Drugs.
“Beaumont congratulates Dr. Cappell for being selected by the FDA to join the Advisory Committee for gastroenterological drugs,” says Ananias Diokno, M.D., executive vice president and chief medical officer, Beaumont Health System. “This appointment is a prestigious honor for Dr. Cappell and Beaumont, as it supports our research and patient care mission, and our role as a national health care leader.”
Members are selected from among authorities knowledgeable in the fields of gastroenterology, endocrinology, surgery, clinical pharmacology, physiology, pathology, liver function, motility, esophagitis and statistics.
Dr. Cappell is a graduate of Albert Einstein College of Medicine. He completed residency programs at Brookdale University Hospital and Medical Center and Montefiore Medical Center both in internal medicine, followed by a gastroenterology fellowship at Columbia Presbyterian Medical Center. He has been named a “Top Doctor) by Castle Connelly in 2012.